Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.

    A Clinical Trial Now Testing a Novel, Engineered Enzyme for Patients with Classical Homocystinuria

    In a recent article appearing in BioPortfolio, Orphan Technologies announced a Phase 1/2 clinical trial involving the first Classical Homocystinuria (HCU) patients to be treated with OT-58. Twelve patients were enrolled as…

    Continue Reading A Clinical Trial Now Testing a Novel, Engineered Enzyme for Patients with Classical Homocystinuria

    Orphan Drug Designation Granted to Therachon’s Drug Apraglutide by FDA for Treatment of Short Bowel Syndrome

    A recent article in CheckOrphan reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the synthetic GLP-2 analog apraglutide for the treatment of short bowel syndrome…

    Continue Reading Orphan Drug Designation Granted to Therachon’s Drug Apraglutide by FDA for Treatment of Short Bowel Syndrome

    One Family’s Struggle with Danon Disease, a Rare Disorder Affecting a Mother and Both of Her Two Young Sons

    In a story published in The Hernando Sun, Dawn Dybiec, age 31, describes her disbelief when she and her husband were told that her two sons, Gabriel and Steven, were…

    Continue Reading One Family’s Struggle with Danon Disease, a Rare Disorder Affecting a Mother and Both of Her Two Young Sons
    Pharnext Announces Preclinical Trial Results Affecting Onset of Charcot-Marie-Tooth Disease 1A
    source: pixabay.com

    Pharnext Announces Preclinical Trial Results Affecting Onset of Charcot-Marie-Tooth Disease 1A

    Pharnext SA, a biopharmaceutical company, recently announced results in a PLOS ONE article entitled "Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A…

    Continue Reading Pharnext Announces Preclinical Trial Results Affecting Onset of Charcot-Marie-Tooth Disease 1A

    Positive Results for aTTP Announced by New England Journal of Medicine

    Patients with acquired thrombotic thrombocytopenic purpura (aTTP) showed a significantly improved platelet count response after treatment with Cablivi® according to the New England Journal of Medicine's Phase 3 trial results. A…

    Continue Reading Positive Results for aTTP Announced by New England Journal of Medicine

    Looking Back With Humor: She Survived and Wrote a Book About How She Fought For Her Children, Her Life, and Her Sanity

    Stephanie Hosford was recently interviewed by CURE (Cancer Updates Research and Education) about what she now calls her “three crazy days”. The title of her book is “Bald, Fat and…

    Continue Reading Looking Back With Humor: She Survived and Wrote a Book About How She Fought For Her Children, Her Life, and Her Sanity